Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 33, 2010, Pages 14845-14850

  Bateup, Helen S ^a   Santini, Emanuela ^b   Shen, Weixing ^c   Birnbaum, Shari ^d   Valjent, Emmanuel ^b   Surmeier, D James ^c   Fisone, Gilberto ^b   Nestler, Eric J ^d,e   Greengard, Paul ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Basal ganglia; DARPP 32; Locomotor behavior; Striatonigral; Striatopallidal

Indexed keywords

DOPAMINE; HALOPERIDOL; LEVODOPA; PHOSPHOPROTEIN DARPP 32; COCAINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; GREEN FLUORESCENT PROTEIN; PPP1R1B PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; BASAL GANGLION; BRAIN NERVE CELL; CATALEPSY; CELL TYPE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RESPONSE; DYSKINESIA; LOCOMOTION; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; CYTOLOGY; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOHISTOCHEMISTRY; LONG TERM POTENTIATION; METABOLISM; MOTOR ACTIVITY; MOUSE MUTANT; NERVE CELL; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC POTENTIAL; TRANSGENIC MOUSE;

MUS;

ANIMALS; CATALEPSY; COCAINE; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOPAMINE UPTAKE INHIBITORS; DYSKINESIA, DRUG-INDUCED; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GREEN FLUORESCENT PROTEINS; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; LEVODOPA; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONAL PLASTICITY; NEURONS; SYNAPTIC POTENTIALS;

EID: 77957098636     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009874107     Document Type: Article

References (34)

1. Graybiel AM (2005) The basal ganglia: Learning new tricks and loving it. Curr Opin Neurobiol 15:638-644.
2. Gerfen CR, et al. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432.
3. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375.
4. Gerfen CR (1992) The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 15:285-320.
5. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104.
6. Farde L, et al. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
7. Mercuri NB, Bernardi G (2005) The "magic" of L-dopa: Why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci 26:341-344.
8. Santini E, et al. (2009) L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108:621-633.
9. Corvol JC, et al. (2004) Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24:7007-7014.
10. Svenningsson P, et al. (2004) DARPP-32: An integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44:269-296.
11. Fienberg AA, et al. (1998) DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission. Science 281:838-842.
12. Gong R, Park CS, Abbassi NR, Tang SJ (2006) Roles of glutamate receptors and the mammalian target of rapamycin (mTOR)-signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biol Chem 281:18802-18815.
13. Deng YP, Lei WL, Reiner A (2006) Differential perikaryal localization in rats of D1 and D2 dopamine receptors on striatal projection neuron types identified by retrograde labeling. J Chem Neuroanat 32:101-116.
14. Rial Verde EM, Lee-Osbourne J, Worley PF, Malinow R, Cline HT (2006) Increased expression of the immediate-early gene arc/arg3.1 reduces AMPA receptor-mediated synaptic transmission. Neuron 52:461-474.
15. Shuen JA, Chen M, Gloss B, Calakos N (2008) Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci 28:2681-2685.
16. Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228-235.
17. Graybiel AM, Aosaki T, Flaherty AW, Kimura M (1994) The basal ganglia and adaptive motor control. Science 265:1826-1831.
18. Reynolds JN, Hyland BI, Wickens JR (2001) A cellular mechanism of reward-related learning. Nature 413:67-70.
19. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30:211-219.
20. Gerfen CR (2003) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist 9:455-462.
21. Santini E, Valjent E, Fisone G (2008) Parkinson's disease: Levodopa-induced dyskinesia and signal transduction. FEBS J 275:1392-1399.
22. Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110-123.
23. Lundblad M, et al. (2005) Pharmacological validation of a mouse model of l-DOPA- induced dyskinesia. Exp Neurol 194:66-75.
24. Fienberg AA, Greengard P (2000) The DARPP-32 knockout mouse. Brain Res Brain Res Rev 31:313-319.
25. Durieux PF, et al. (2009) D2R striatopallidal neurons inhibit both locomotor and drug reward processes. Nat Neurosci 12:393-395.
26. Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2:119-128.
27. Xu M, Guo Y, Vorhees CV, Zhang J (2000) Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res 852:198-207.
28. Xu M, et al. (1994) Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79: 945-955.
29. Chausmer AL, Katz JL (2001) The role of D2-like dopamine receptors in the locomotor stimulant effects of cocaine in mice. Psychopharmacology (Berl) 155:69-77.
30. Liu XY, et al. (2006) Modulation of D2R-NR2B interactions in response to cocaine. Neuron 52:897-909.
31. Santini E, et al. (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27:6995-7005.
32. Darmopil S, Martin AB, Diego IR, Ares S, Moratalla R (2009) Genetic inactivation of dopamine d1 but not d2 receptors inhibits l-dopa-induced dyskinesia and histone activation. Biol Psychiatry 66:603-613.
33. Valjent E, et al. (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA 102:491-496.
34. Gerfen CR, Paletzki R, Worley P (2008) Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine- and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase. J Neurosci 28:7113-7120.